CD19‐Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia
- 10 September 2015
- journal article
- review article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 82 (4), 307-319
- https://doi.org/10.1111/sji.12331
Abstract
Adoptive cell therapy (ACT) for cancer represents a promising new treatment modality. ACT based on the administration of cytotoxic T cells genetically engineered to express a chimeric antigen receptor (CAR) recognizing CD19 expressed by B cell malignancies has been shown to induce complete lasting responses in patients with chronic lymphocytic leukaemia (CLL) and acute lymphoblastic leukaemia (ALL). So far, eleven clinical trials including 99 CLL and ALL patients treated with CAR T cells targeting CD19 have been published, and the results from these trials are promising with impressive clinical responses in heavily pretreated patients. Thus, CAR T cell therapy has induced complete responses in both CLL and ALL, and surprisingly, current results indicate that patients with ALL are more prone to respond than are CLL patients. Importantly, the majority of CAR cell studies have observed severe therapy-associated toxicities, which needs attention. Herein we review current data and discuss key aspects of this powerful approach to treat and potentially cure B cell malignancies.Keywords
This publication has 71 references indexed in Scilit:
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen ReceptorJournal of Clinical Oncology, 2015
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2014
- Cancer treatment and survivorship statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Antibody-modified T cells: CARs take the front seat for hematologic malignanciesBlood, 2014
- CAR T cells: driving the road from the laboratory to the clinicImmunological Reviews, 2013
- T-cell adoptive immunotherapy for acute lymphoblastic leukemiaHematology-American Society Hematology Education Program, 2013
- Targeting tumours with genetically enhanced T lymphocytesNature Reviews Cancer, 2003
- CD19 Antigen in Leukemia and Lymphoma Diagnosis and ImmunotherapyLeukemia & Lymphoma, 1995
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.Proceedings of the National Academy of Sciences, 1993
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.Proceedings of the National Academy of Sciences, 1989